These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 31647951)

  • 1. A Multicompany Assessment of Submicron Particle Levels by NTA and RMM in a Wide Range of Late-Phase Clinical and Commercial Biotechnology-Derived Protein Products.
    Hubert M; Yang DT; Kwok SC; Rios A; Das TK; Patel A; Wuchner K; Antochshuk V; Junge F; Bou-Assaf GM; Cao S; Saggu M; Montrond L; Afonina N; Kolhe P; Loladze V; Narhi L
    J Pharm Sci; 2020 Jan; 109(1):830-844. PubMed ID: 31647951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection and Sizing of Submicron Particles in Biologics With Interferometric Scattering Microscopy.
    Wong NA; Uchida NV; Dissanayake TU; Patel M; Iqbal M; Woehl TJ
    J Pharm Sci; 2020 Jan; 109(1):881-890. PubMed ID: 31160046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of Nanoparticle Tracking Analysis for Quantification and Sizing of Submicron Particles of Therapeutic Proteins.
    Zhou C; Krueger AB; Barnard JG; Qi W; Carpenter JF
    J Pharm Sci; 2015 Aug; 104(8):2441-50. PubMed ID: 26017684
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative Laser Diffraction for Quantification of Protein Aggregates: Comparison With Resonant Mass Measurement, Nanoparticle Tracking Analysis, Flow Imaging, and Light Obscuration.
    Yoneda S; Niederleitner B; Wiggenhorn M; Koga H; Totoki S; Krayukhina E; Friess W; Uchiyama S
    J Pharm Sci; 2019 Jan; 108(1):755-762. PubMed ID: 30237029
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interference from Proteins and Surfactants on Particle Size Distributions Measured by Nanoparticle Tracking Analysis (NTA).
    Bai K; Barnett GV; Kar SR; Das TK
    Pharm Res; 2017 Apr; 34(4):800-808. PubMed ID: 28155075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of Inherent Particles and Mechanism of Thermal Stress Induced Particle Formation in HSV-2 Viral Vaccine Candidate.
    Li L; Kirkitadze M; Bhandal K; Roque C; Yang E; Carpick B; Rahman N
    Curr Pharm Biotechnol; 2017 Nov; 18(8):638-647. PubMed ID: 28914197
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Biopharmaceutical Industry Perspective on the Control of Visible Particles in Biotechnology-Derived Injectable Drug Products.
    Mathonet S; Mahler HC; Esswein ST; Mazaheri M; Cash PW; Wuchner K; Kallmeyer G; Das TK; Finkler C; Lennard A
    PDA J Pharm Sci Technol; 2016; 70(4):392-408. PubMed ID: 27091885
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Application of a Best Practice Approach Using Resonant Mass Measurement for Biotherapeutic Product Characterization.
    Krueger AB; Hadley J; Cheney PP; Markova N; Carpenter JF; Fradkin AH
    J Pharm Sci; 2019 May; 108(5):1675-1685. PubMed ID: 30599170
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Closing the Gap: Counting and Sizing of Particles Across Submicron Range by Flow Cytometry in Therapeutic Protein Products.
    Zhang L; Shi S; Antochshuk V
    J Pharm Sci; 2017 Nov; 106(11):3215-3221. PubMed ID: 28625725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of submicron (0.1-1 μm) particles in therapeutic proteins by nanoparticle tracking analysis.
    Vasudev R; Mathew S; Afonina N
    J Pharm Sci; 2015 May; 104(5):1622-31. PubMed ID: 25737284
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Critical evaluation of Nanoparticle Tracking Analysis (NTA) by NanoSight for the measurement of nanoparticles and protein aggregates.
    Filipe V; Hawe A; Jiskoot W
    Pharm Res; 2010 May; 27(5):796-810. PubMed ID: 20204471
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Contribution of Intravenous Administration Components to Subvisible and Submicron Particles Present in Administered Drug Product.
    Pollo M; Mehta A; Torres K; Thorne D; Zimmermann D; Kolhe P
    J Pharm Sci; 2019 Jul; 108(7):2406-2414. PubMed ID: 30849460
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analyzing subvisible particles in protein drug products: a comparison of dynamic light scattering (DLS) and resonant mass measurement (RMM).
    Panchal J; Kotarek J; Marszal E; Topp EM
    AAPS J; 2014 May; 16(3):440-51. PubMed ID: 24570341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Subvisible (2-100 μm) particle analysis during biotherapeutic drug product development: Part 2, experience with the application of subvisible particle analysis.
    Corvari V; Narhi LO; Spitznagel TM; Afonina N; Cao S; Cash P; Cecchini I; DeFelippis MR; Garidel P; Herre A; Koulov AV; Lubiniecki T; Mahler HC; Mangiagalli P; Nesta D; Perez-Ramirez B; Polozova A; Rossi M; Schmidt R; Simler R; Singh S; Weiskopf A; Wuchner K
    Biologicals; 2015 Nov; 43(6):457-73. PubMed ID: 26324466
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Comprehensive Evaluation of Nanoparticle Tracking Analysis (NanoSight) for Characterization of Proteinaceous Submicron Particles.
    Tian X; Nejadnik MR; Baunsgaard D; Henriksen A; Rischel C; Jiskoot W
    J Pharm Sci; 2016 Nov; 105(11):3366-3375. PubMed ID: 27663383
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Critical Evaluation of Microfluidic Resistive Pulse Sensing for Quantification and Sizing of Nanometer- and Micrometer-Sized Particles in Biopharmaceutical Products.
    Grabarek AD; Weinbuch D; Jiskoot W; Hawe A
    J Pharm Sci; 2019 Jan; 108(1):563-573. PubMed ID: 30176253
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of Incremental Siliconization Levels on Soluble Aggregates, Submicron and Subvisible Particles in a Prefilled Syringe Product.
    Bai S; Landsman P; Spencer A; DeCollibus D; Vega F; Temel DB; Houde D; Henderson O; Brader ML
    J Pharm Sci; 2016 Jan; 105(1):50-63. PubMed ID: 26852839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subvisible (2-100 μm) Particle Analysis During Biotherapeutic Drug Product Development: Part 1, Considerations and Strategy.
    Narhi LO; Corvari V; Ripple DC; Afonina N; Cecchini I; Defelippis MR; Garidel P; Herre A; Koulov AV; Lubiniecki T; Mahler HC; Mangiagalli P; Nesta D; Perez-Ramirez B; Polozova A; Rossi M; Schmidt R; Simler R; Singh S; Spitznagel TM; Weiskopf A; Wuchner K
    J Pharm Sci; 2015 Jun; 104(6):1899-1908. PubMed ID: 25832583
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of Tubing Type, Formulation, and Postpumping Agitation on Nanoparticle and Microparticle Formation in Intravenous Immunoglobulin Solutions Processed With a Peristaltic Filling Pump.
    Her C; Carpenter JF
    J Pharm Sci; 2020 Jan; 109(1):739-749. PubMed ID: 31108051
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Practical Considerations for Detection and Characterization of Sub-Micron Particles in Protein Solutions by Nanoparticle Tracking Analysis.
    Gruia F; Parupudi A; Polozova A
    PDA J Pharm Sci Technol; 2015; 69(3):427-39. PubMed ID: 26048748
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.